Current Treatment Options in Oncology

, Volume 1, Issue 5, pp 387–398 | Cite as

Gastroesophageal junction adenocarcinoma

  • Stephen G. Swisher
  • Peter W. T. Pisters
  • Ritsuko Komaki
  • Sandeep Lahoti
  • Jaffer A. Ajani

Opinion statement

The incidence rate of adenocarcinoma of the esophagogastric junction (AEG) is increasing in association with the epidemiologic rise in distal esophageal adenocarcinoma and gastric cardial (AEG type III) tumors [1-4]. The overall survival rate is poor in most patients with AEG because lymph node or visceral metastases are frequently present at the time patients become symptomatic [5]. A few patients are identified early in the disease because of screening for gastroesophageal reflux and Barrett's esophagus [6,7].

Early stage AEG (T1N0 or T2NO, carcinoma in situ, or severe dysplasia [50% risk of developing adenocarcinoma in 5 years]) can in many instances be cured with surgery alone. Ablative treatments for early stage AEG, including endoscopic fulguration by cautery and laser or photodynamic therapy, are investigational at this time [8].

Locoregionally advanced AEG (T3, T4, N1, or M1a [nonregional lymph nodes]) without distant systemic metastases (M1b) has a poor overall survival rate with surgery alone or definitive chemotherapy and radiation therapy without surgery [9,10,11].

Analysis of the use of multimodality treatment strategies for locoregionally advanced AEG types I and II have demonstrated improved survival rates in two small phase III trials with preoperative concurrent chemoradiotherapy followed by surgical resection [12,13]. In contrast, three small phase III trials with preoperative concurrent or sequential chemoradiotherapy in patients with predominantly squamous cell carcinoma did not demonstrate any clear survival advantage [14-16]. Additionally, a randomized phase III study evaluating preoperative chemotherapy without radiation therapy in esophageal cancer (predominantly adenocarcinoma) has demonstrated no survival benefit [10]. In light of these results, additional large randomized phase III studies are needed to confirm the potential benefit of preoperative concurrent chemoradiotherapy. At the present time, preoperative chemoradiotherapy remains investigational.

For locoregionally advanced gastric adenocarcinoma, including AEG type III, postoperative concurrent 5-fluorouracil (5-FU)-based chemoradiotherapy is associated with improved survival as demonstrated in a recently completed random assignment trial (INT 0116) [17,18]. As a result, surgery with postoperative chemoradiotherapy has recently become the standard of care for patients with AJCC stage II and III gastric adenocarcinoma (including patients with AEG type III).

Metastatic AEG (M1b) should be treated with palliative chemotherapy (in good performance patients) or supportive care (poor performance) in asymptomatic patients. Radiation therapy and endoscopic stent placement (expandable wire mesh) can be used to palliate dysphagia in patients with M1b disease. The development of expandable stents and improved radiotherapy has obviated surgical bypass to palliate patients with symptomatic, metastatic AEG.


Esophageal Cancer Proximal Gastrectomy Transhiatal Esophagectomy Main Side Effect Nausea Expandable Metal Stents 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Powell J, McConkey CC: The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992, 1:265–269.PubMedCrossRefGoogle Scholar
  2. 2.
    Pera M, Cameron AJ, Trastek VF, et al.: Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993, 104:510–513.PubMedGoogle Scholar
  3. 3.
    Siewert JR, Stein HJ, Sendler A, Fink U: Surgical resection for cancer of the cardia. Semin Surg Oncol 1999, 17:125–131.PubMedCrossRefGoogle Scholar
  4. 4.
    Siewert JR: Adenocarcinoma of the gastroesophageal junction: classification, pathology and extent of resection. Dis Esophagus 1996, 9:173–182.Google Scholar
  5. 5.
    Swisher SG, Hunt KK, Holmes EC, et al.: Changes in the surgical management of esophageal cancer from 1970 to 1993. Am J Surg 1995, 169:609–614.PubMedCrossRefGoogle Scholar
  6. 6.
    Robertson CS, Mayberry JF, Nicholson DA, et al.: Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988, 75:760–763.PubMedCrossRefGoogle Scholar
  7. 7.
    Peters JH, Clark GW, Ireland AP, et al.: Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovas Surg 1994, 108:813–822.Google Scholar
  8. 8.
    Lightdale CJ, Heier S, Marcon NE, et al.: Photodynamic therapy with profimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer; a multicenter randomized trial. Gastrointest Endosc 2000, 42:507–512.CrossRefGoogle Scholar
  9. 9.
    Herskovic A, Martz K, Al-Sarraf M, et al.: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326:1593–1598. This randomized study showed that the combination of chemotherapy and radiation therapy was better than radiation therapy alone. Additionally, it suggested that in locoregionally advanced esophageal cancer, survival rates could be achieved that were similar to surgery but with a higher locoregional failure rate (40% at 1 year).PubMedCrossRefGoogle Scholar
  10. 10.
    Kelsen DP, Ginsberg R, Pajak TF, et al.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339:1979–1984. This randomized study demonstrated that preoperative chemotherapy offered no overall survival advantage over surgery alone in esophageal cancer.PubMedCrossRefGoogle Scholar
  11. 11.
    Swisher SG, Holmes EC, Hunt KK, et al.: The role of neoadjuvant therapy in surgically resectable esophageal cancer. Arch Surg 1996, 131:819–825.PubMedGoogle Scholar
  12. 12.
    Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462–467. This randomized study showed a significant survival advantage in patients with distal esophageal adenocarcinoma treated with preoperative concurrent chemoradiotherapy followed by surgery versus surgery alone.PubMedCrossRefGoogle Scholar
  13. 13.
    Urba S, Orringer M, Turrisi A, et al.: A randomized trial comparing surgery (S) to pre-operative concomitant chemoradiation plus surgery in patients (pts) with resectable esophageal cancer (CA): updated analysis. Proc Am Soc Clin Oncol 1997, 16:277a.Google Scholar
  14. 14.
    Le Prise E, Etienne PL, Meunier B, et al.: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994, 73:1779–1784.PubMedCrossRefGoogle Scholar
  15. 15.
    Bosset JF, Gignoux M, Triboulet JP, et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997, 337:161–167. A randomized trial that showed no survival advantage with concurrent preoperative chemoradiotherapy. This trial evaluated predominantly squamous cell carcinoma and administered the concurrent radiation in a different schedule than the positive trials with preoperative concurrent chemoradiation.PubMedCrossRefGoogle Scholar
  16. 16.
    Nygaard K, Hagen S, Hansen HS, et al.: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian Trail in Esophageal Cancer. World J Surg 1992, 16:1104–1110.PubMedCrossRefGoogle Scholar
  17. 17.
    Hermans J, Bonekamp JJ, Boon MC, et al.: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993, 11:1441–1447.PubMedGoogle Scholar
  18. 18.
    MacDonald JS, Smalley S, Benedetti J, et al.: Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and g.e. junction. Proc Am Soc Clin Oncol 2000, 19:9. This preliminary abstract was presented at the American Society of Clinical Oncology and demonstrated improved survival with postoperative chemoradiation in patients with gastric and type III AEG versus surgery alone.Google Scholar
  19. 19.
    Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr. JF: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287–1289.PubMedCrossRefGoogle Scholar
  20. 20.
    Reed PI: Changing pattern of oesophageal cancer. Lancet 1991, 338:178–178.CrossRefGoogle Scholar
  21. 21.
    Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825–831.PubMedCrossRefGoogle Scholar
  22. 22.
    Resbeut M, Chenal C, Vignoud J, et al.: Results of a randomized neoadjuvant program of chemotherapy before surgery and/or radiotherapy in the treatment of 156 esophageal carcinomas. Second Int Cong on Neo-Adjuv Chem, 1988:49.Google Scholar
  23. 23.
    Ellul J, Watkinson A, Khan R, et al.: Self-expanding metal stents for the palliation of dysphagia due to inoperable oesophageal carcinoma. Br J Surg 1998, 82:1678–1681.CrossRefGoogle Scholar
  24. 24.
    Raijman I, Siddique I, Ajani J, Lynch P: Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc 1998, 1998:172–179.CrossRefGoogle Scholar
  25. 25.
    VanRensburg S: Epidemiologic and dietary evidence for a specific nutritional predisposition to esophageal cancer. J Natl Cancer Inst 1981, 67:243–251.Google Scholar
  26. 26.
    International Agency for Research on Cancer: Alcohol drinking. Hum Pathol 1988, 44:1–378.Google Scholar
  27. 27.
    Blot WJ: Alcohol and cancer. Cancer Res 1992, 52:2119S-2123S.PubMedGoogle Scholar
  28. 28.
    Ghadirian P, Stein G, Gorodetzky C, et al.: Oesophageal cancer studies in the Caspian littoral of Iran: some residual results, including opium use as a risk factor. Int J Cancer 1985, 35:593–597.PubMedCrossRefGoogle Scholar
  29. 29.
    VanRensburg S, Bradshaw E, Bradshaw D, Rose E: Esophageal cancer in Zulu men, South Africa. Br J Cancer 1985, 51:399–405.Google Scholar
  30. 30.
    Wynder EL, Bross IJ: A study of etiological factors in cancer of the esophagus. Cancer 1961, 14:389–413.PubMedCrossRefGoogle Scholar
  31. 31.
    Yu MC, Garabrant DH, Peters JM, Mack TM: Tobacco, alcohol, diet, occupation, and carcinoma of the esophagus. Cancer Res 1988, 48:3843–3848.PubMedGoogle Scholar
  32. 32.
    Blot WJ, Li JY, Taylor PR, et al.: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993, 85:1483–1492.PubMedCrossRefGoogle Scholar
  33. 33.
    Swisher SG, DeFord L, Merriman KW, et al.: Effect of operative volume on morbidity, mortality and hospital utilization following esophagectomy for cancer. J Thorac Cardiovasc Surg 2000, 119:1126–1134.PubMedCrossRefGoogle Scholar
  34. 34.
    Okawa T, Kita M, Tanaka M, Ikeda M: Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1989, 17:49–54.PubMedGoogle Scholar
  35. 35.
    Acunas B, Rozanes I, Akpinar S, et al.: Palliation of malignant esophageal strictures with self-expanding Nitinol stents. Radiology 1999, 733:648–652.Google Scholar
  36. 36.
    Nicholson A, Royston C, Wedgewood K, et al.: Palliation of malignant oesophageal perforation and proximal oesophageal malignant dysphagia with covered metal stents. Clin Radiol 1995, 50:11–14.PubMedCrossRefGoogle Scholar
  37. 37.
    Kinsman KJ, DeGregorio BT, Katon RM, et al.: Prior radiation and chemotherapy increase in risk of life-threatening complications after insertion of metallic stents for esophagogastric malignancy. Gastrointest Endosc 1996, 43:196–203.PubMedCrossRefGoogle Scholar
  38. 38.
    Takeshita K, Saito N, Saeki I, et al.: Proximal gastrectomy and jejunal pouch interposition for the treatment of early cancer in the upper third of the stomach: surgical techniques and evaluation of postoperative function. Surgery 1997, 121:278–286.PubMedCrossRefGoogle Scholar
  39. 39.
    Gaissert HA, Mathisen D, Grillo H, et al.: Short-segment intestinal interposition of the distal esophagus. J Thorac Cardiovasc Surg 1993, 106:860–867.PubMedGoogle Scholar
  40. 40.
    Mansour K, Bryan C, Carlson GW: Bowel interposition for esophageal replacement: twenty-five-year experience. Ann Thorac Surg 1997, 64:752–756.PubMedCrossRefGoogle Scholar
  41. 41.
    Thomas P, Fuentes P, Giudicelli R, Reboud E: Colon interposition for esophageal replacement: current indications and long-term function. Ann Thorac Surg 1997, 64:757–764.PubMedCrossRefGoogle Scholar
  42. 42.
    Bonenkamp JJ, Hermans J, Sasako M, et al.: Extended lymph-node dissection for gastric cancer. N Engl J Med 1995, 340:908–914.CrossRefGoogle Scholar
  43. 43.
    Bonenkamp JJ, Songun I, Hermans J, et al.: Randomized comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995, 345:745–748.PubMedCrossRefGoogle Scholar
  44. 44.
    Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomized controlled surgical trial. Lancet 1996, 347:995–999.PubMedCrossRefGoogle Scholar
  45. 45.
    Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: longterm results of the MRC randomized surgical trial. Br J Cancer 1999, 79:1522–1530.PubMedCrossRefGoogle Scholar
  46. 46.
    Bunt A, Hermans J, Boon MC, et al.: Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer. J Clin Oncol 1994, 12:417–422.PubMedGoogle Scholar
  47. 47.
    Nishimaki T, Suzuki T, Kanda T, et al.: Extended radical esophagectomy for superficially invasive carcinoma of the esophagus. Surgery 1999, 125:142–147.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Stephen G. Swisher
    • 1
  • Peter W. T. Pisters
    • 2
  • Ritsuko Komaki
    • 3
  • Sandeep Lahoti
    • 4
  • Jaffer A. Ajani
    • 4
  1. 1.Department of Thoracic and Cardiovascular SurgeryUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Surgical OncologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  3. 3.Department of Radiation OncologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  4. 4.Department of Gastrointestinal OncologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations